SYF90e04de1560e4d499bc0dc44f1e46799Registry ID: 2024-514181-39-00|RecruitingPhase 3
ISEE-RCC study
Intrapatient comparison of 68Ga-gozetotide (PSMA) PET and 89Zr-girentuximab PET in clear cell renal cell carcinoma (ISEE-RCC)
Loading search results
Intrapatient comparison of 68Ga-gozetotide (PSMA) PET and 89Zr-girentuximab PET in clear cell renal cell carcinoma (ISEE-RCC)
interventional
N/A
1 country
1
This explorative study aims to investigate and compare (both visually and semi-quantitatively) the tumor detection rates of 68Ga-gozetotide (PSMA) PET and 89Zr-DFO-girentuximab PET in patients suspected of having primary, recurrent or metastatic ccRCC.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 23, 2024
Actual (reported)To evaluate the tumor detectability/detection rate (descriptive) of 68Ga-gozetotide (PSMA) PET-CT compared to 89Zr-DFO-girentuximab PET-CT (both in addition to conventional contrast enhanced CT) in patients with the suspicion of metastatic ccRCC. The denominator will consist of the conventional diagnostic contrast enhanced CT, 68Ga-gozetotide (PSMA) PET-CT and 89Zr-DFO-girentuximab PET-CT.
The semi-quantitative assessment of the SUVmax in primary tumor (if in situ) and SUVmax of metastases (lesion based analyses).
Tumor-to-background ratio of primary tumor (if in situ) and tumor-to-background ratio of metastases.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Stichting Radboud universitair medisch centrum
Nijmegen, 6525 GA, Netherlands
dr. Stijn Muselaers
First Submitted
October 23, 2024
Download the complete CTIS (EMA) record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: European Medicines Agency (EMA), Clinical Trials Information System (CTIS). Original record and public documents are available on CTIS.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved:
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.